Amerikanische Gesellschaft für Hirudotherapie

Management options for pediatric venous thromboembolic disease: Beyond anticoagulation with endovascular therapies.

Review published in Thrombosis research (2024)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienArzneimittelentwicklungMitta et al. · Thrombosis research, 2024

Abstract

Venous thromboembolism (VTE) in pediatric patients is an uncommon but serious diagnosis that has an array of therapeutic options and challenges. An assessment of the existing literature on management of pediatric patients with VTE was conducted. The interventions reviewed include anticoagulation, thrombolysis, thrombectomy, inferior vena cava (IVC) filters, and venous stenting. For each intervention, a discussion of mechanism of action, indications, contraindications, and potential complications was performed. While anticoagulants are considered the first-line pediatric VTE treatment, many drugs remain investigational in this patient population and treatment recommendations are extrapolated from adult practice. Thrombolysis may be indicated in cases of acute thrombosis requiring more rapid clot resolution but presents a greater bleeding risk than anticoagulation. Similarly, thrombectomy also provides rapid clot resolution and offers a larger therapeutic window and usage in more mature thrombi than thrombolysis. In select patient groups, IVC filters may be indicated in the prevention of PE but present with inherent thrombogenicity and risk of migration. The data regarding pediatric VTE treatment options, monitoring, and long term outcomes is limited compared to the adult population. The relatively few clinical trials including pediatric patients have a relatively small sample size and are heterogenous with regards to predisposing factors that further exacerbate generalizability. Additional research is needed to help construct and evaluate a robust treatment algorithm for pediatric patients with VTE.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansVenous ThromboembolismAnticoagulantsChildEndovascular ProceduresThrombolytic TherapyThrombectomyVena Cava Filters

Zusammenfassung

Venous thromboembolism (VTE) in pediatric patients is an uncommon but serious diagnosis that has an array of therapeutic options and challenges. An assessment of the existing literature on management of pediatric patients with VTE was conducted.

Warum dies für die Hirudotherapie relevant ist

This review assesses the existing literature on management of pediatric venous thromboembolic disease, including anticoagulation, thrombolysis, thrombectomy, inferior vena cava filters, and venous stenting, with discussion of mechanisms, indications, contraindications, and complications for each. The authors note that while anticoagulants are first-line treatment, many drugs remain investigational in pediatric populations and data on monitoring and long-term outcomes is limited. The abstract contains no mention of leeches, hirudotherapy, leech-derived compounds, or the leech secretome. There is no defensible connection to ASH's domain, as the review evaluates conventional endovascular therapies and pharmaceutical agents exclusively.

Zitation

Management options for pediatric venous thromboembolic disease: Beyond anticoagulation with endovascular therapies.

Mitta et al. · Thrombosis research, 2024

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.